Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carbamazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharma gets USFDA Nod for Generic Drug
Details : Carbamazepine is an anticonvulsant and specific analgesic, works by blocking sodium alpha subunit channels, it is indicated for trigeminal neuralgia.
Product Name : Tegretol-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2025
Lead Product(s) : Carbamazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALG-000184,Carbamazepine,Itraconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Details : ALG-000184 is a potent potential best/first-in-class oral small molecule capsid assembly modulator (CAM-E) being developed for chronic hepatitis B.
Product Name : ALG-000184
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 22, 2024
Lead Product(s) : ALG-000184,Carbamazepine,Itraconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carbamazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP
Details : Upsher-Smith’s product is AB-rated to the branded product, Tegretol® XR (carbamazepine extended-release tablets). The carbamazepine extended-release tablet market had U.S. sales of approximately $120 million for the 12 months ending June 2021 accordin...
Product Name : Carbamazepine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Carbamazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable